|Dr. Gregory A. Demopulos||Co-Founder, Chairman, CEO & Pres||2.24M||N/A||1959|
|Mr. Michael A. Jacobsen||Chief Accounting Officer, VP of Fin. & Treasurer||543.75k||N/A||1958|
|Mr. Peter B. Cancelmo J.D.||VP, Gen. Counsel & Corp. Sec.||409.11k||N/A||1979|
|Dr. Pamela Pierce Palmer||Co-Founder||N/A||N/A||1963|
|Dr. George A. Gaitanaris M.D., Ph.D.||Chief Scientific Officer & VP of Science||N/A||N/A||1957|
|Mr. Peter W. Williams||VP of HR||N/A||N/A||1968|
|Dr. J. Steven Whitaker||VP of Clinical Devel. & Chief Medical Officer||N/A||N/A||1956|
|Dr. Catherine A. Melfi||Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems||N/A||N/A||1959|
|Ms. Nadia Dac||Chief Commercial Officer||N/A||N/A||1970|
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation’s ISS governance QualityScore as of 1 July 2021 is 8. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 5; Compensation: 7.